VITARI

At a genomics conference in February, Element Biosciences unveiled VITARI: a benchtop DNA sequencer about the size of a mini-fridge that reads a person's full genome for roughly $100 in consumables. It lists at $689,000, opens for pre-order now, and ships in the second half of 2026.

A mid-size hospital lab that could never justify a million-dollar instrument can plausibly justify this one.

The eye-catching number is not where the news is. A $100 genome is no longer a frontier — Illumina quotes it to its biggest committed buyers, and a rival, Ultima, claims $80. What VITARI changes is who can afford the box that does it. Illumina's high-throughput NovaSeq X lists between roughly $985,000 and $1.25 million and is sized for a sequencing center; VITARI delivers about a fifth of that throughput — some ten billion DNA reads per run, enough for population- and clinical-scale work — from a machine that fits on a bench at half the capital cost.

So the competition has quietly moved. When every major vendor advertises the same per-genome floor, the question stops being how cheap each run is and becomes who can buy in at all. A mid-size hospital lab or research institute that could never justify a million-dollar instrument can plausibly justify this one — which widens the set of places that can run sequencing at scale, even as the headline price stays put.